Budecort

Turbuhaler: Bronchial asthma. Respules: Bronchial asthma requiring treatment w/ glucocorticosteroids for control of the underlying airway inflammation for maintenance treatment & acute exacerbations. Exacerbations of COPD. Croup (acute viral URTI also known as viral laryngotracheobronchitis or laryngitis subglottica) in infants & childn.

Turbuhaler Individualized dosage. Adult 200-800 mcg/day, divided into 2-4 inhalations. More severe cases Up to 1,600 mcg may be needed. Full dose may be given in 1 administration w/ daily doses up to 400 mcg. Childn ≥6 yr 100-800 mcg/day, divided into 2-4 inhalations. Full dose may be given in 1 administration w/ daily doses up to 400 mcg. Respules Maintenance treatment for bronchial asthma Individualized dosage. Administration can be once daily or bid. Once daily administration can be used for 250-1,000 mcg daily doses & can be initiated in non-corticosteroid treated patient & patient well-controlled by inhaled glucocorticosteroids. Adult & elderly Initially, 1,000-2,000 mcg daily. Maintenance: 500-4,000 mcg daily, may be further increased in very severe cases. Childn ≥6 mth 250-500 mcg daily. Maintenance: 250-2,000 mcg daily. Acute exacerbations of asthma Adult 4-8 mg daily, divided into 1-4 administrations, may be further increased in very severe cases. Max dose at 1 occasion should not exceed 4 mg. Childn 6 mth to 17 yr 1.5-4 mg daily, divided into 1-4 administrations. Up to 6 mg can be considered in childn ≥5 yr. Max dose at 1 occasion should not exceed 3 mg. Exacerbations of COPD 4-8 mg daily, divided into 2-4 administrations. Croup Childn & infant 2 mg as a single dose or as two 1 mg doses separated by 30 min, can be repeated every 12-36 hr.

Hypersensitivity.

Rinse mouth w/ water after each dose in order to minimise risk of Candida infections in the oral cavity & throat. Avoid concomitant treatment w/ ketoconazole, itraconazole or other potent CYP3A4 inhibitors. Risk of impaired adrenal function in patients transferring from oral steroids or patients who have required high dose emergency corticosteroid therapy or prolonged treatment at the highest recommended dose of inhaled corticosteroids; consider additional systemic corticosteroid cover during periods of stress or elective surgery. Patients may experience return of previous symptoms eg, muscle & joint pain during transfer from oral steroid therapy or during w/drawal phase; temporary increase of oral steroid dose may be necessary. Replacement of systemic steroid treatment sometimes reveals allergies eg, rhinitis & eczema previously controlled by the systemic treatment. Regularly monitor growth in childn & adolescents receiving long-term treatment w/ corticosteroids. Increased exposure may be expected in patients w/ severe liver cirrhosis. Pregnancy. Turbuhaler: Patients transferred from systemically acting corticosteroids & in cases of suspected disturbance of pituitary-adrenocortical function; consider cautious systemic steroid dose reduction, & hypothalamic-pituitary-adrenocortical function tests. Supplement w/ short-course oral steroids if there is sudden treatment deterioration. No experience of treatment in patients w/ impaired hepatic or renal function. Lactation. Respules: Not intended for rapid relief of acute episodes of asthma where an inhaled short-acting bronchodilator is required. Consider the need for increased anti-inflammatory therapy eg, higher doses of inhaled budesonide or course of oral glucocorticosteroid if short-acting bronchodilator treatment is ineffective, or more inhalations are needed than usual.

Mild irritation in the throat, Candida infection in the oropharynx, hoarseness, coughing.

Increased plasma levels or systemic exposure w/ potent CYP3A4 inhibitors eg, ketoconazole & itraconazole.

Antiasthmatic & COPD Preparations

R03BA02 - budesonide ; Belongs to the class of other inhalants used in the treatment of obstructive airway diseases, glucocorticoids.

Rx